Status:
COMPLETED
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
Lead Sponsor:
Allergan
Conditions:
Retinitis Pigmentosa
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This exploratory, 12-month, ascending-dose study will evaluate the safety and effects on visual function of a single injection of Brimonidine intravitreal implant in one eye of patients with Retinitis...
Eligibility Criteria
Inclusion
- Retinitis Pigmentosa in both eyes
- Visual acuity between 20/40 to count fingers
Exclusion
- Growth of new blood vessels in the eye
- Any intraocular surgery or laser in either eye in the last 6 months prior to Screening visit or between the Screening visit and Day 1
- Any ocular disease that can interfere with diagnosis and or assessment of disease progression
- Significant near-sightedness
- HIV
- Female patients who are pregnant, nursing, or planning pregnancy
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00661479
Start Date
July 1 2008
End Date
May 1 2010
Last Update
April 24 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Arlington, Texas, United States
2
Paris, France
3
Tübingen, Germany
4
Coimbra, Portugal